Benzinga | Dec 1, 2020 08:09AM EST

Outlook Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

MONMOUTH JUNCTION, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), alate clinical-stagebiopharmaceutical companyworking to develop the first FDA-approved ophthalmic formulation of bevacizumabfor use in retinalindications, announced today that it has received notification from Nasdaq that it has regained compliance with the minimum bid price for continued listing on the Nasdaq Capital Market, as the closing bid price of Outlook Therapeutics' common stock has been at $1.00 or greater for 10 consecutive trading days. Accordingly, this matter is now closed.